{"version":"1.0","provider_name":"hollandbio","provider_url":"https:\/\/www.hollandbio.nl\/en\/","title":"NewAmsterdam Pharma acquires Obicetrapib from Amgen - hollandbio","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"FZwM32jQFw\"><a href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/newamsterdam-pharma-acquires-obicetrapib-from-amgen\/\">NewAmsterdam Pharma acquires Obicetrapib from Amgen<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/newamsterdam-pharma-acquires-obicetrapib-from-amgen\/embed\/#?secret=FZwM32jQFw\" width=\"600\" height=\"338\" title=\"&#8220;NewAmsterdam Pharma acquires Obicetrapib from Amgen&#8221; &#8212; hollandbio\" data-secret=\"FZwM32jQFw\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.hollandbio.nl\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"NewAmsterdam Pharma B.V. (\u201cNAP\u201d) has acquired the rights to Obicetrapib (AMG 899) from Amgen. The new Company, spearheaded by Michael Davidson, MD (CEO) and John Kastelein, MD, PhD, FESC (CSO), is currently working with the U.S. Food and Drug Administration (FDA) on a comprehensive phase 3 clinical development program, including a cardiovascular outcome trial (CVOT) [&hellip;]","thumbnail_url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","thumbnail_width":1200,"thumbnail_height":675}